Atorvastatin drug interactions
Searched over 200M research papers
Summary
10 papers analyzed
Some studies suggest atorvastatin has no significant interaction with fenofibrate or EZE, while other studies indicate significant interactions with cytochrome P450-3A4 inhibitors, HIV-protease inhibitors, hepatitis C virus protease inhibitors, and certain other drugs, potentially increasing the risk of adverse effects like myopathy or rhabdomyolysis.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Atorvastatin Drug Interactions: A Comprehensive Overview
Introduction to Atorvastatin and Its Metabolism
Atorvastatin is a widely prescribed statin used to lower cholesterol levels and prevent cardiovascular diseases. It is metabolized primarily by the cytochrome P450 (CYP) 3A4 enzyme and undergoes extensive metabolism in the liver and gut, producing several active metabolites, including 2-hydroxy-atorvastatin acid and atorvastatin lactone. Understanding the drug-drug interactions (DDIs) of atorvastatin is crucial for optimizing its therapeutic efficacy and minimizing adverse effects.
Atorvastatin and Cytochrome P450 Inhibitors
Interaction with Cyclosporin A (CsA)
In renal transplant recipients treated with cyclosporin A (CsA), atorvastatin has been shown to increase CsA blood levels in some patients. Specifically, four out of ten patients experienced a rise in CsA levels by more than 25% within 7-14 days of starting atorvastatin therapy. This interaction necessitates careful monitoring and potential dose adjustments of CsA when co-administered with atorvastatin.
Interaction with Antiviral Protease Inhibitors
Atorvastatin, metabolized by CYP3A4, interacts with antiviral protease inhibitors (PIs) such as ritonavir and cobicistat, which are potent CYP3A inhibitors. These interactions can significantly increase atorvastatin levels, leading to a higher risk of adverse effects like myopathy and rhabdomyolysis. Therefore, it is recommended to start atorvastatin at the lowest possible dose and monitor for adverse effects when co-administered with these PIs.
Interaction with Other CYP3A4 Inhibitors
Atorvastatin's pharmacokinetics are also affected by other CYP3A4 inhibitors such as itraconazole, clarithromycin, and verapamil. These inhibitors can increase atorvastatin's area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax), necessitating dose adjustments to avoid toxicity.
Atorvastatin and Organic Anion Transporting Polypeptides (OATP) Inhibitors
Atorvastatin is a substrate for OATP1B1/1B3, which facilitates its hepatic uptake. Inhibitors of these transporters, such as cyclosporine and rifampin, can increase atorvastatin exposure, leading to higher plasma levels and an increased risk of adverse effects . Clinicians should be aware of these interactions and adjust atorvastatin doses accordingly.
Atorvastatin and Other Lipid-Lowering Agents
Fenofibrate
A study investigating the co-administration of atorvastatin and fenofibrate found no significant pharmacokinetic interaction between the two drugs. The combination did not alter the AUC or Cmax of atorvastatin, suggesting that they can be safely co-administered without dose adjustments.
Ezetimibe
Similarly, the combination of atorvastatin and ezetimibe showed no relevant pharmacokinetic interaction. The AUC and Cmax of atorvastatin were not significantly affected by ezetimibe, indicating that this combination is also safe for concurrent use.
Atorvastatin and Omega-3 Fatty Acids
A phase 1 trial evaluating the interaction between atorvastatin and omega-3 fatty acids revealed a pharmacokinetic interaction. The co-administration resulted in changes in the pharmacokinetic parameters of both atorvastatin and its metabolites, suggesting that dose adjustments may be necessary when these agents are used together.
Conclusion
Atorvastatin is subject to various drug-drug interactions, primarily mediated by CYP3A4 and OATP1B1/1B3. These interactions can significantly alter atorvastatin's pharmacokinetics, necessitating careful monitoring and dose adjustments to avoid adverse effects. While some combinations, such as with fenofibrate and ezetimibe, do not pose significant interaction risks, others, particularly with potent CYP3A4 inhibitors and OATP inhibitors, require cautious co-administration. Understanding these interactions is crucial for optimizing atorvastatin therapy and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic
